Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All DataMeds AI, Inc. filings on SEC EDGAR ↗
DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.
DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) reported a net income of $10.5 million for the quarter ended September 30, 2026, primarily driven by a $19.1 million gain on debt extinguishment. However, the company experienced a significant decline in nine-month revenues from $21.7 million in 2025 to $6.0 million in 2026, resulting in a year-to-date net loss of $15.6 million.
DataMEDS AI reported Q3 2026 revenue of $2.7 million, representing 50% sequential growth driven by its Corexa Pharmacy drug dispensing business. The company achieved a net profit of $2.72 per share and regained full compliance with Nasdaq listing standards during the period. Key strategic developments included the launch of the Health Lives Here mobile app and the acquisition of the Helomics cancer diagnostics laboratory.
Term
Q3 2026
“Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions.”